Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood flow drug help restore skin color in vitiligo?

NCT ID NCT07775105

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether a topical medication called pentoxifylline, typically used to improve blood flow, can help restore skin color in people with stable vitiligo. It compares this approach to another topical drug, 5-fluorouracil, and to microneedling alone, with all patients also receiving narrow-band UVB phototherapy. The study involves 42 participants, each with three vitiligo patches treated differently, and measures repigmentation using a physician-rated scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical pentoxifylline or topical 5-fluorouracil, each combined with microneedling and narrow-band UVB phototherapy
What this could lead to
If effective, this could offer a new topical option to restore skin color in people with stable vitiligo.
What could go wrong
This is a small, early-stage trial, and results may not apply to all vitiligo patients. Treatments may cause skin irritation or fail to produce significant repigmentation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Jan 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with stable vitiligo. No new or progressive vitiligo lesions for at least 1 year. No vitiligo treatment for at least 3 months. Age 6-55 years based on the enrolled study population Exclusion Criteria: * History of keloidal tendency. Bleeding tendency. Current anticoagulant therapy. Pregnancy or breastfeeding. Presence of other systemic or dermatological diseases. Contraindications to phototherapy. Photosensitive disorders, including lupus erythematosus or xeroderma pigmentosum. Personal or family history of skin cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microneedling-assisted delivery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Microneedling-assisted delivery Phototherapy Vitiligo vulgaris

Contacts and locations

Locations

  • Tanta University Hospitals

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.